BMS (NYSE: BMY) Gets EC Approval for Breyanzi in MCL, 82.7% Response, 71.6% CR

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)--Nov 24, 2025-

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)--Nov 24, 2025-

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

In the TRANSCEND MCL trial, 82.7% of patients responded to Breyanzi, with 71.6% of patients achieving complete response Breyanzi demonstrated sustained clinical benefit, with 50.8% of patients still in response at 24 months based on TRANSCEND MCL trial results PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Breyanzi--Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has [...] The post Bristol Myers Squibb Receives Approv…

BMS (NYSE: BMY) gets EC approval for Breyanzi in MCL, 82.7% response, 71.6% CR

EC approves Breyanzi for relapsed or refractory MCL after ≥2 prior therapies including a BTK inhibitor, with 50.8% of patients still in response at 24 months.